NXL — Nexalin Technology Inc.
NASDAQ · Healthcare · Medical Devices
$6.42
-$0.38 (-5.59%)
Nexalin Technology Inc. (NXL) is a medical devices company listed on NASDAQ. It is led by Mark White, based in 1776 Yorktown, Houston, TX, United States, 77056, with about 8 employees. Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer's disease, and dementia. Nexalin Technology, Inc. is headquartered in Houston, Texas.
Latest reported NXL revenue for 2025-09-30 was $18.1K. Net income was -$2.3M. Revenue was down 74.3% from 2025-06-30 to 2025-09-30. NXL currently screens at market cap $8.5M.
Use this NXL page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the NXL quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the NXL SEC filings page. Lician reads the product cache first so this HTML stays unique to Nexalin Technology Inc. even when a live quote feed is slow.
About Nexalin Technology Inc.
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer's disease, and dementia. Nexalin Technology, Inc. is headquartered in Houston, Texas.
NXL Key Statistics
Market Cap
$8.47M
Volume
72,870
Previous Close
$0.32
Day Range
$0.30 – $0.32
P/B Ratio
2.91
EPS
-$0.83
Revenue
$168.72K
Net Income
-$7.61M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+52.3%
Profit Margin
-4508.7%
Employees
8
NXL Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $168.72K | $110.75K | $1.32M | $144.06K |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$7.61M | -$4.65M | -$1.70M | -$6.08M |
| EPS (Diluted) | -$0.83 | -$0.63 | -$0.30 | $0.00 |
Total Assets
$4.22M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$574.49K
Operating Cash Flow
-$3.94M
Free Cash Flow
$0.00
Nexalin Technology Inc. Company Information
- President, CEO & Director
- Mark White
- Headquarters
- 1776 Yorktown, Houston, TX, United States, 77056
- Website
- www.nexalin.com
- Phone
- 832 260 0222
- IPO / Founded
- 2022-09-16
- Sector
- Healthcare
- Industry
- Medical Devices